Why Pfizer Is Tapping Private Equity for Its Once-Monthly Weight-Loss Drug
FROM THE WIRE · BARRONS.COM
Blackstone Life Sciences agrees to pay $1.5 billion in development costs for Pfizer's berobenatide through 2028 in exchange for milestone-based payments.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA $1.5 billion development funding deal may ease Pfizer's development costs.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Blackstone Life Sciences agrees to pay $1.5 billion in development costs through 2028.
- 02In exchange it receives milestone-based payments.
- 03The drug involved is Pfizer's berobenatide.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets